H
Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics is a comprehensive high-tech design company
About Hangzhou Just Biotherapeutics (Just China)
Hangzhou Just Biotherapeutics (HJB), operating as the contract development and manufacturing organization (CDMO) arm of Transcenta Holding Limited, provides specialized services for large-molecule biotherapeutics. The company was founded in August 2016 by Dr. Jonathan Y. Zhao, a former executive at Amgen, along with other industry veterans. HJB was established as a sister company to the Seattle-based Just Biotherapeutics Inc., which was co-founded by Dr. Zhao and other Amgen alumni in 2015.
In a significant milestone, HJB merged with MabSpace Biosciences in January 2019 to form Transcenta Holding Ltd., creating a fully integrated biotherapeutics company. This strategic merger combined HJB's process development and manufacturing strengths with MabSpace's discovery and clinical research capabilities. Following the merger, Dr. Jonathan Y. Zhao assumed the role of executive chairman, while Dr. Xueming Qian, the founder of MabSpace, became the CEO of Transcenta. Transcenta successfully completed its initial public offering on the Hong Kong Stock Exchange on September 29, 2021.
The company's business model is centered on providing end-to-end CDMO services to biotechnology and pharmaceutical firms, covering the entire lifecycle from development to manufacturing. HJB generates revenue by offering a comprehensive suite of services, including cell line and process development, analytical services, formulation, and both drug substance (DS) and drug product (DP) manufacturing under cGMP standards. Its clientele consists of companies requiring accelerated development and cost-effective manufacturing for their biologic drug candidates for preclinical studies through to commercial launch. HJB operates in the global biopharmaceutical CDMO market, with facilities in Hangzhou, China, designed to meet international quality standards.
HJB's core service is anchored by advanced technology platforms designed to accelerate timelines and reduce production costs. A key feature is its modular manufacturing facility (T-BLOC) and the implementation of an Integrated Continuous Bioprocessing (HiCB) platform. These systems are designed to enhance efficiency, improve process control, and lower the cost of goods for complex biologics like monoclonal antibodies and fusion proteins. The service portfolio is extensive, ranging from initial material generation for research and developability assessment to late-stage process characterization and regulatory filing support for IND applications in both China and the US.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jun 2018 | $35M | $140M | Undisclosed | — |
| SERIES BOther financing | Aug 2017 | $55M | $220M | Temasek · ARCH Venture Partners · Lilly Asia Ventures · Bank of China | — |
Growth signals
Latest recorded traffic for Hangzhou Just Biotherapeutics (Just China) is 430 monthly website visits, up 115% over the last three months. Hangzhou Just Biotherapeutics (Just China)'s team grew 3.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Hangzhou Just Biotherapeutics (Just China) in the Hangzhou ecosystem
The Hangzhou Just Biotherapeutics (Just China) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Bill & Melinda Gates Foundation
Series A5 investors entered at this stage
ARCH Venture Partners
Lilly Asia Ventures
Temasek
Bank of China- HVHEDA Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Hangzhou Just Biotherapeutics (Just China) on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Hangzhou Just Biotherapeutics (Just China)’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








